Dearborn Partners LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 197,828 shares of the biopharmaceutical company’s stock after selling 7,078 shares during the period. Dearborn Partners LLC’s holdings in Gilead Sciences were worth $14,172,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the stock. SeaCrest Wealth Management LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $347,000. Global Trust Asset Management LLC acquired a new stake in Gilead Sciences in the fourth quarter worth $897,000. US Bancorp DE increased its position in Gilead Sciences by 3.1% in the fourth quarter. US Bancorp DE now owns 1,118,454 shares of the biopharmaceutical company’s stock worth $80,126,000 after buying an additional 33,981 shares during the period. Aperio Group LLC increased its position in Gilead Sciences by 7.1% in the fourth quarter. Aperio Group LLC now owns 970,482 shares of the biopharmaceutical company’s stock worth $69,525,000 after buying an additional 64,620 shares during the period. Finally, Telemus Capital LLC acquired a new stake in Gilead Sciences in the fourth quarter worth $589,000. 77.96% of the stock is currently owned by institutional investors and hedge funds.
In related news, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the completion of the transaction, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John C. Martin sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold 430,268 shares of company stock valued at $34,074,395 in the last ninety days. Company insiders own 1.30% of the company’s stock.
Several brokerages have weighed in on GILD. Vetr lowered Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 target price on the stock. in a research report on Monday, January 29th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $88.80 to $76.00 in a research report on Tuesday, January 30th. Morgan Stanley dropped their target price on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Bank of America increased their target price on Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 7th. Finally, BMO Capital Markets increased their target price on Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $88.61.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $81.72 on Wednesday. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The company has a market capitalization of $106,186.01, a price-to-earnings ratio of 9.49, a PEG ratio of -1.86 and a beta of 1.24. The company has a current ratio of 2.74, a quick ratio of 2.67 and a debt-to-equity ratio of 1.53.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter last year, the business posted $2.70 earnings per share. The company’s quarterly revenue was down 18.7% on a year-over-year basis. sell-side analysts predict that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 annualized dividend and a yield of 2.79%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio (DPR) is currently 59.77%.
TRADEMARK VIOLATION NOTICE: This report was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/03/14/gilead-sciences-inc-gild-shares-sold-by-dearborn-partners-llc.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.